Cipla (CIPLA) — Financial Results

Cipla reported Q3 FY25 revenue of ₹7,073 crores, up 8% YoY, with PAT at ₹1,571 crores and EBITDA margin expanding to 28% from prior-year levels. The company highlighted strong growth in India's consumer wellness segment, rising from ₹250 crores to ₹380 crores quarter-on-quarter, and confirmed broad revenue growth expectations for FY'26 driven by US respiratory launches. Capital allocation priorities include dividend growth to 30% of profits, targeted acquisitions, and sustained R&D investment. Management noted progress on US FDA compliance, with InvaGen facility reinspection pending, and anticipated Abraxane launch in H2 FY'26 following regulatory approval. R&D spend remained steady at 5% of revenue, supporting pipeline advancements in complex injectables and oligonucleotides over a 3-5 year horizon.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this financial results affect Cipla Limited's outlook?" "What did Cipla Limited announce on 31 January 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 31 January 2025

SUNPHARMA Sun Pharmaceutical Industries Limited Corporate Action SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results TATACONSUM TATA CONSUMER PRODUCTS LIMITED Financial Results SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.